FUSIONEN VON PRKACB

Patent europeic · EP3221700 · Stritgà

Inscripziun en il register

Numer da publicaziun
EP3221700
Numer da la dumonda
EP15802296
Gener
Patent europeic cun effect per la Svizra ed il Liechtenstein
Status
Stritgà
Scrittira da patent
Concedì
Annunzià
17-11-2015
Publitgà
27-09-2017
Concedì
22-06-2022
Stritgà
23-06-2023
Motiv
Taxa annuala betg pajada
Classas IPC
G01N 33/574 (2006.01)
Prioritad
US 201462081445 P 18.11.2014
Dumonda PCT
PCT/US2015/061073 17.11.2015
Publicaziun PCT
WO2016/081450 26.05.2016
Lingua da l’annunzia
englais
Funtauna
Swissreg

Istorgia

Quai che l’Institut federal da la proprietad intellectuala ha publitgà davart quest titel, il pli nov l’emprim.

  1. 23-06-2023

    Stritgà, taxa betg pajada

    Published in Swissreg on 23.06.2023

  2. 03-05-2023

    Midada

    Published in Swissreg on 03.05.2023

  3. 22-06-2022

    Concedì

    Published in Swissreg on 22.06.2022

Partidas

Possessur

Blueprint Medicines Corporation

38 Sidney Street, suite 200, Cambridge, MA 02139, US

Inventur

STRANSKY, Nicolas

Charlestown, MA 02129, US

Il register numna mintga partida cun num ed adressa. In possessur u in represchentant vegn collià cun in’organisaziun, sch’exact ina unitad giuridica dal register da commerzi porta ses num; la via d’ina partida betg enconuschida uschia na vegn betg mussada qua.